{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:33:17Z","timestamp":1769632397110,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jgar.2022.02.007","type":"journal-article","created":{"date-parts":[[2022,2,13]],"date-time":"2022-02-13T17:26:16Z","timestamp":1644773176000},"page":"7-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0524-3434","authenticated-orcid":false,"given":"Jen-Yu","family":"Hsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0074-7721","authenticated-orcid":false,"given":"Hsin-Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1508-5417","authenticated-orcid":false,"given":"Tan-Wen","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sui-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Shan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2474-2968","authenticated-orcid":false,"given":"Ching-Yu","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ching","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Fang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7345-0836","authenticated-orcid":false,"given":"Chien-Ching","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.02.007_bib0001","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","article-title":"HIV drug resistance against strand transfer integrase inhibitors","volume":"14","author":"Anstett","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.jgar.2022.02.007_bib0002","unstructured":"World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. 2017. https:\/\/www.who.int\/hiv\/pub\/guidelines\/advanced-HIV-disease\/en\/."},{"key":"10.1016\/j.jgar.2022.02.007_bib0003","unstructured":"European AIDS Clinical Society. EACS guidelines version 11.0. 2021. https:\/\/www.eacsociety.org\/media\/final2021eacsguidelinesv11.0_oct2021.pdfhttps:\/\/www.eacsociety.org\/media\/final2021eacsguidelinesv11.0_oct2021.pdf"},{"key":"10.1016\/j.jgar.2022.02.007_bib0004","unstructured":"DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. 2021. https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf."},{"key":"10.1016\/j.jgar.2022.02.007_bib0005","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2022.02.007_bib0006","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2022.02.007_bib0007","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.02.007_bib0008","series-title":"Conference on Retroviruses and Opportunistic Infections","article-title":"HIV viral blips in adults treated with INSTI-based regimens through 144 weeks","author":"Acosta","year":"2020"},{"key":"10.1016\/j.jgar.2022.02.007_bib0009","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S1473-3099(17)30681-3","article-title":"Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study","volume":"18","author":"Hermans","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2022.02.007_bib0010","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/QAI.0000000000001678","article-title":"Low-level viremia is associated with clinical progression in HIV-infected patients receiving antiretroviral treatment","volume":"78","author":"Bernal","year":"2018","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2022.02.007_bib0011","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/cid\/ciz129","article-title":"Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure","volume":"69","author":"Joya","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.02.007_bib0012","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12879-020-4837-y","article-title":"Factors associated with high-risk low-level viremia leading to virologic failure: 16-year retrospective study of a Chinese antiretroviral therapy cohort","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2022.02.007_bib0013","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12981-021-00336-0","article-title":"Predictors of virological failure among people living with HIV receiving first line antiretroviral treatment in Myanmar: retrospective cohort analysis","volume":"18","author":"Mesic","year":"2021","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jgar.2022.02.007_bib0014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3851\/IMP2815","article-title":"Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study","volume":"20","author":"Boillat-Blanco","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2022.02.007_bib0015","doi-asserted-by":"crossref","first-page":"19668","DOI":"10.7448\/IAS.17.4.19668","article-title":"A retrospective observational study of low-level viraemia and its immunological and virological significance: which outcome to expect","volume":"17","author":"Silva","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jgar.2022.02.007_bib0016","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/hiv.12413","article-title":"Very low level viraemia and risk of virological failure in treated HIV-1-infected patients","volume":"18","author":"Teira","year":"2017","journal-title":"HIV Med"},{"key":"10.1016\/j.jgar.2022.02.007_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104534","article-title":"Evaluation of virological response and resistance profile in HIV-1 infected patients starting a first-line integrase inhibitor-based regimen in clinical settings","volume":"130","author":"Armenia","year":"2020","journal-title":"J Clin Virol"},{"key":"10.1016\/j.jgar.2022.02.007_bib0018","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1086\/378301","article-title":"Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance","volume":"37","author":"Sethi","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.02.007_bib0019","doi-asserted-by":"crossref","first-page":"19667","DOI":"10.7448\/IAS.17.4.19667","article-title":"Difference in factors associated with low-level viraemia and virological failure: results from the Austrian HIV Cohort Study","volume":"17","author":"Leierer","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jgar.2022.02.007_bib0020","article-title":"Lower incidence of HIV-1 blips observed during integrase inhibitor-based combination antiretroviral therapy","author":"Dijkstra","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2022.02.007_bib0021","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ijid.2021.02.045","article-title":"Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy","volume":"105","author":"Chen","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2022.02.007_bib0022","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.02.007_bib0023","first-page":"111","article-title":"2019 update of the drug resistance mutations in HIV-1","volume":"27","author":"Wensing","year":"2019","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.jgar.2022.02.007_bib0024","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","volume":"379","author":"DeJesus","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2022.02.007_bib0025","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"Sax","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2022.02.007_bib0026","doi-asserted-by":"crossref","first-page":"ofaa316","DOI":"10.1093\/ofid\/ofaa316","article-title":"Virological failure and acquired genotypic resistance associated with contemporary antiretroviral treatment regimens","volume":"7","author":"Rhee","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2022.02.007_bib0027","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1473-3099(14)70796-0","volume":"14","author":"Pozniak","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2022.02.007_bib0028","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(14)70782-0","volume":"14","author":"Arribas","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2022.02.007_bib0029","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/jac\/dkx018","article-title":"Switch as maintenance to elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate: week 48 results in a clinical cohort","volume":"72","author":"Perrier","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.02.007_bib0030","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1097\/QAD.0000000000002194","article-title":"Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting","volume":"33","author":"Davy-Mendez","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2022.02.007_bib0031","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1093\/jac\/dkaa287","article-title":"Impact of archived M184V\/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV","volume":"75","author":"Chen","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.02.007_bib0032","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAI.0000000000002589","article-title":"Efficacy and safety of elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide as maintenance treatment in HIV\/HBV-coinfected patients","volume":"86","author":"Huang","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2022.02.007_bib0033","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijid.2019.12.029","article-title":"Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide","volume":"92","author":"Kuo","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2022.02.007_bib0034","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11584570-000000000-00000","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir","volume":"50","author":"Ramanathan","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2022.02.007_bib0035","first-page":"1","article-title":"Possible herb-drug interaction risk of some nutritional and beauty supplements on antiretroviral therapy in HIV patients","author":"Haron","year":"2020","journal-title":"J Diet Suppl"},{"key":"10.1016\/j.jgar.2022.02.007_bib0036","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1097\/QAD.0000000000002967","article-title":"Use of dietary supplements containing polyvalent cations and antacids among people living with HIV and its impact on viral suppression","volume":"35","author":"Peng","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2022.02.007_bib0037","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1473-3099(19)30036-2","article-title":"Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial","volume":"19","author":"Aboud","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2022.02.007_bib0038","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijantimicag.2019.03.016","article-title":"Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients","volume":"54","author":"Chen","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2022.02.007_bib0039","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/jac\/dkz424","article-title":"Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study","volume":"75","author":"Modica","year":"2020","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652200039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221371652200039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:00:50Z","timestamp":1761991250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221371652200039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":39,"alternative-id":["S221371652200039X"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.02.007","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}